Ab interno trabecular bypass surgery with iStent for open-angle glaucoma

Jimmy T. Le, Amanda K. Bicket, Lin Wang, Tianjing Li

Research output: Contribution to journalReview article

Abstract

Glaucoma is a leading cause of irreversible blindness worldwide. In early stages, glaucoma results in progressive loss of peripheral (side) vision; in later stages, it results in loss of central vision leading to blindness. Elevated intraocular pressure (IOP) is the only known modifiable risk factor for glaucoma. Minimally invasive glaucoma surgical (MIGS) techniques, such as ab interno trabecular bypass surgery with iStent (Glaukos Corporation, Laguna Hills, CA, USA), have been introduced as a new treatment modality for glaucoma. However, the effectiveness of MIGS on keeping people drop-free (i.e. not having to use eye drops to control IOP) and other outcomes is uncertain. Objectives To assess the effectiveness and safety of ab interno trabecular bypass surgery with iStent (or iStent inject) for open-angle glaucoma in comparison to conventional medical, laser, or surgical treatment. Search methods Cochrane Eyes and Vision s Information Specialist searched the following databases on 17 August 2018: the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register; 2018, Issue 7), MEDLINE Ovid, Embase Ovid, the ISRCTN registry, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We applied no date or language restrictions. We searched the reference lists of reports from included studies. Selection criteria We included randomized controlled trials (RCTs) that had compared iStent or iStent inject to medical therapy, laser treatment, conventional glaucoma surgery (trabeculectomy), or other MIGS procedures. We included RCTs that had compared iStent or iStent inject in combination with phacoemulsification to phacoemulsification alone. Data collection and analysis We used standard methodological procedures expected by Cochrane. Two review authors independently screened search results, assessed risk of bias, and extracted data from reports of included RCTs using an electronic data collection form.

Original languageEnglish (US)
Article numberCD012743
JournalCochrane Database of Systematic Reviews
Volume2019
Issue number3
DOIs
StatePublished - Mar 28 2019

Fingerprint

Open Angle Glaucoma
Glaucoma
Phacoemulsification
Randomized Controlled Trials
Blindness
Intraocular Pressure
Registries
Trabeculectomy
Information Services
Minimally Invasive Surgical Procedures
Ophthalmic Solutions
Laser Therapy
MEDLINE
Patient Selection
Lasers
Language
Therapeutics
Clinical Trials
Databases
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ab interno trabecular bypass surgery with iStent for open-angle glaucoma. / Le, Jimmy T.; Bicket, Amanda K.; Wang, Lin; Li, Tianjing.

In: Cochrane Database of Systematic Reviews, Vol. 2019, No. 3, CD012743, 28.03.2019.

Research output: Contribution to journalReview article

@article{fa15cd6bb1414b6bb6b33e388a84d962,
title = "Ab interno trabecular bypass surgery with iStent for open-angle glaucoma",
abstract = "Glaucoma is a leading cause of irreversible blindness worldwide. In early stages, glaucoma results in progressive loss of peripheral (side) vision; in later stages, it results in loss of central vision leading to blindness. Elevated intraocular pressure (IOP) is the only known modifiable risk factor for glaucoma. Minimally invasive glaucoma surgical (MIGS) techniques, such as ab interno trabecular bypass surgery with iStent (Glaukos Corporation, Laguna Hills, CA, USA), have been introduced as a new treatment modality for glaucoma. However, the effectiveness of MIGS on keeping people drop-free (i.e. not having to use eye drops to control IOP) and other outcomes is uncertain. Objectives To assess the effectiveness and safety of ab interno trabecular bypass surgery with iStent (or iStent inject) for open-angle glaucoma in comparison to conventional medical, laser, or surgical treatment. Search methods Cochrane Eyes and Vision s Information Specialist searched the following databases on 17 August 2018: the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register; 2018, Issue 7), MEDLINE Ovid, Embase Ovid, the ISRCTN registry, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We applied no date or language restrictions. We searched the reference lists of reports from included studies. Selection criteria We included randomized controlled trials (RCTs) that had compared iStent or iStent inject to medical therapy, laser treatment, conventional glaucoma surgery (trabeculectomy), or other MIGS procedures. We included RCTs that had compared iStent or iStent inject in combination with phacoemulsification to phacoemulsification alone. Data collection and analysis We used standard methodological procedures expected by Cochrane. Two review authors independently screened search results, assessed risk of bias, and extracted data from reports of included RCTs using an electronic data collection form.",
author = "Le, {Jimmy T.} and Bicket, {Amanda K.} and Lin Wang and Tianjing Li",
year = "2019",
month = "3",
day = "28",
doi = "10.1002/14651858.CD012743.pub2",
language = "English (US)",
volume = "2019",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Ab interno trabecular bypass surgery with iStent for open-angle glaucoma

AU - Le, Jimmy T.

AU - Bicket, Amanda K.

AU - Wang, Lin

AU - Li, Tianjing

PY - 2019/3/28

Y1 - 2019/3/28

N2 - Glaucoma is a leading cause of irreversible blindness worldwide. In early stages, glaucoma results in progressive loss of peripheral (side) vision; in later stages, it results in loss of central vision leading to blindness. Elevated intraocular pressure (IOP) is the only known modifiable risk factor for glaucoma. Minimally invasive glaucoma surgical (MIGS) techniques, such as ab interno trabecular bypass surgery with iStent (Glaukos Corporation, Laguna Hills, CA, USA), have been introduced as a new treatment modality for glaucoma. However, the effectiveness of MIGS on keeping people drop-free (i.e. not having to use eye drops to control IOP) and other outcomes is uncertain. Objectives To assess the effectiveness and safety of ab interno trabecular bypass surgery with iStent (or iStent inject) for open-angle glaucoma in comparison to conventional medical, laser, or surgical treatment. Search methods Cochrane Eyes and Vision s Information Specialist searched the following databases on 17 August 2018: the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register; 2018, Issue 7), MEDLINE Ovid, Embase Ovid, the ISRCTN registry, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We applied no date or language restrictions. We searched the reference lists of reports from included studies. Selection criteria We included randomized controlled trials (RCTs) that had compared iStent or iStent inject to medical therapy, laser treatment, conventional glaucoma surgery (trabeculectomy), or other MIGS procedures. We included RCTs that had compared iStent or iStent inject in combination with phacoemulsification to phacoemulsification alone. Data collection and analysis We used standard methodological procedures expected by Cochrane. Two review authors independently screened search results, assessed risk of bias, and extracted data from reports of included RCTs using an electronic data collection form.

AB - Glaucoma is a leading cause of irreversible blindness worldwide. In early stages, glaucoma results in progressive loss of peripheral (side) vision; in later stages, it results in loss of central vision leading to blindness. Elevated intraocular pressure (IOP) is the only known modifiable risk factor for glaucoma. Minimally invasive glaucoma surgical (MIGS) techniques, such as ab interno trabecular bypass surgery with iStent (Glaukos Corporation, Laguna Hills, CA, USA), have been introduced as a new treatment modality for glaucoma. However, the effectiveness of MIGS on keeping people drop-free (i.e. not having to use eye drops to control IOP) and other outcomes is uncertain. Objectives To assess the effectiveness and safety of ab interno trabecular bypass surgery with iStent (or iStent inject) for open-angle glaucoma in comparison to conventional medical, laser, or surgical treatment. Search methods Cochrane Eyes and Vision s Information Specialist searched the following databases on 17 August 2018: the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register; 2018, Issue 7), MEDLINE Ovid, Embase Ovid, the ISRCTN registry, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We applied no date or language restrictions. We searched the reference lists of reports from included studies. Selection criteria We included randomized controlled trials (RCTs) that had compared iStent or iStent inject to medical therapy, laser treatment, conventional glaucoma surgery (trabeculectomy), or other MIGS procedures. We included RCTs that had compared iStent or iStent inject in combination with phacoemulsification to phacoemulsification alone. Data collection and analysis We used standard methodological procedures expected by Cochrane. Two review authors independently screened search results, assessed risk of bias, and extracted data from reports of included RCTs using an electronic data collection form.

UR - http://www.scopus.com/inward/record.url?scp=85063612894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063612894&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD012743.pub2

DO - 10.1002/14651858.CD012743.pub2

M3 - Review article

VL - 2019

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 3

M1 - CD012743

ER -